Abstract:Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The development of domain-selective BET inhibitors to separate efficacy and toxicity is urgently needed. Herein, we report a series of furo[3,2-c]pyridin-4(5H)-one derivatives as novel BD2-selective BET inhibitors. The representative compound 8l (XY153) potently bound to BRD4 BD2 with an half-maximum inhibitory concentration (IC50) value of 0.79 nM and displayed 354-fold selectivity over BRD4 BD1. Besides, 8l exhibited 6-fold BRD4 BD2 domain selectivity over other BET BD2 domains. Compound 8l displayed potent antiproliferative activity against multiple tumor cell lines, especially MV4-11 (IC50 = 0.55 nM), while showing weak cytotoxicity against the normal lung fibroblast cell line. It highlights the safety profile of this series of BD2 inhibitors. 8l also demonstrated good metabolic stability in vitro. These data indicate that 8l may serve as a new and valuable lead compound for the development of potential therapeutics against acute myeloid leukemia (AML).The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c00100.Statistics of the data set and structure refinement of 7o, 7u, 8a, 8f, 8k, and 8l (Table S1); Kon, Koff, and Kd values of 8l, 8m, and 3 in the BLI assay (Table S2); inhibition rates of 8j–m, and 3 by alphascreen (Table S3); IC50 values of 8l and 3 in different cell lines (Table S4); structure overlap of 8k with 4 in BRD2 BD2 (Figure S1); dose–response curves of 8l, 8m, and 3 in the BLI assay (Figure S2); binding affinity of compounds 7b, 7r, 7y, 8j, 8k, 8l, 8m, and 1 in the TSA assay (Figure S3); melting curves of 8l, 8m, and 1 in the TSA assay (Figure S4); inhibitory curve of compounds 8l and 3 in different cell lines (Figure S5); 1H NMR and 13C NMR for all final compounds; and HPLC traces for 8h–m (PDF)Molecular formula strings for compounds with associated biological data (CSV)Homology models for the core structure with BRD2 BD2 (PDB)Crystal (X-ray) structure validation reports for compound 7o (PDF)Crystal (X-ray) structure validation reports for compound 7u (PDF)Crystal (X-ray) structure validation reports for compound 8a (PDF)Crystal (X-ray) structure validation reports for compound 8f (PDF)Crystal (X-ray) structure validation reports for compound 8k (PDB: 7WMQ) (PDF)Crystal (X-ray) structure validation reports for compound 8l (PDB: 7WLN) (PDF)Crystal (X-ray) structure validation reports for compound 8k (PDB: 7WJS) (PDF)Crystal (X-ray) structure validation reports for compound 8l (PDB: 7WKY) (PDF)This article has not yet been cited by other publications.

Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors

Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases

Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development

Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections

Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain

Selective inhibition of BET bromodomains

Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia

Structure-Based Discovery and Optimization of Furo[3,2- c ]pyridin-4(5 H )-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors

Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.

Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1 H-pyrrolo[2,3- c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.

Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors

Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.

Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy

Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development

Successes and challenges in the development of BD1-selective BET inhibitors: a patent review

The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors